Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Snapinn

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Pharmaceutical Statistics|October 7, 2022
Treatment effect measures under nonproportional hazardsSteven Snapinn, Qi Jiang, Chunlei Ke
Biometrics|September 2, 2004
Calculation of sample size in survival trials: the impact of informative noncomplianceQi Jiang, Steven Snapinn, Boris Iglewicz
Statistics in Medicine|May 4, 2004
The role of the unblinded sponsor statisticianSteven Snapinn, Thomas Cook, Deborah Shapiro, et al.
American Heart Journal|October 18, 2003
Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study)Thao Huynh, Pierre Theroux, Steven Snapinn, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical TrialsHaijun Ma, Chunlei Ke, Qi Jiang, et al.
Pharmaceutical Statistics|November 28, 2006
Assessment of futility in clinical trialsSteven Snapinn, Mon-Gy Chen, Qi Jiang, et al.
International Journal of Cardiology|March 29, 2008
Moderate alcohol consumption is associated with reduced long-term cardiovascular risk in patients following a complicated acute myocardial infarctionTrygve Brügger-Andersen, Volker Pönitz, Steven Snapinn, et al.
Statistics in Medicine|February 21, 2012
Predicting analysis time in event-driven clinical trials with event-reporting lagJianming Wang, Chunlei Ke, Qi Jiang, et al.
The American Journal of Cardiology|March 5, 2004
Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failureAina Hognestad, Kenneth Dickstein, Eivind Myhre, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Choosing Appropriate Metrics to Evaluate Adverse Events in Safety EvaluationYing Zhou, Chunlei Ke, Qi Jiang, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Pharmaceutical Statistics|October 7, 2022
Treatment effect measures under nonproportional hazardsSteven Snapinn, Qi Jiang, Chunlei Ke
Biometrics|September 2, 2004
Calculation of sample size in survival trials: the impact of informative noncomplianceQi Jiang, Steven Snapinn, Boris Iglewicz
Statistics in Medicine|May 4, 2004
The role of the unblinded sponsor statisticianSteven Snapinn, Thomas Cook, Deborah Shapiro, et al.
American Heart Journal|October 18, 2003
Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study)Thao Huynh, Pierre Theroux, Steven Snapinn, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical TrialsHaijun Ma, Chunlei Ke, Qi Jiang, et al.
Pharmaceutical Statistics|November 28, 2006
Assessment of futility in clinical trialsSteven Snapinn, Mon-Gy Chen, Qi Jiang, et al.
International Journal of Cardiology|March 29, 2008
Moderate alcohol consumption is associated with reduced long-term cardiovascular risk in patients following a complicated acute myocardial infarctionTrygve Brügger-Andersen, Volker Pönitz, Steven Snapinn, et al.
Statistics in Medicine|February 21, 2012
Predicting analysis time in event-driven clinical trials with event-reporting lagJianming Wang, Chunlei Ke, Qi Jiang, et al.
The American Journal of Cardiology|March 5, 2004
Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failureAina Hognestad, Kenneth Dickstein, Eivind Myhre, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Choosing Appropriate Metrics to Evaluate Adverse Events in Safety EvaluationYing Zhou, Chunlei Ke, Qi Jiang, et al.
Pageof 4